Valuation: Omeros Corporation

Market Cap 1.32B 1.15B 1.08B 982M 1.84B 127B 1.85B 12.92B 4.98B 64.34B 4.97B 4.86B 205B P/E 2026 *
20.5x
P/E 2027 * 18.3x
Enterprise Value 1.32B 1.15B 1.08B 982M 1.84B 127B 1.85B 12.92B 4.98B 64.34B 4.97B 4.86B 205B EV / Sales 2026 *
10.5x
EV / Sales 2027 * 6.69x
Free-Float
95.92%
Yield 2026 *
-
Yield 2027 * -
1 day-3.61%
1 week-8.05%
Current month-6.44%
1 month+2.27%
3 months+88.42%
6 months+57.81%
Current year+2.36%
1 week 17.56
Extreme 17.56
19.55
1 month 16.9
Extreme 16.9
19.65
Current year 6.7
Extreme 6.7023
19.65
1 year 3.94
Extreme 3.94
19.65
3 years 0.92
Extreme 0.92
19.65
5 years 0.92
Extreme 0.92
19.65
10 years 0.92
Extreme 0.92
27.09
Manager TitleAgeSince
Chief Executive Officer 67 16/06/1994
Director of Finance/CFO 62 30/06/2024
Chief Tech/Sci/R&D Officer 70 01/11/2019
Director TitleAgeSince
Chairman 67 16/06/1994
Director/Board Member 86 01/01/1995
Director/Board Member 72 01/01/1995
Date Insider Type Main position Quantity % Market Cap. Importance
31/08/26 Exercice

General Counsel

75,000 0.1036%
27/08/26 Exercice

Director

30,000 0.0415%
24/08/26 Exercice

Chief Financial Officer

2,718 0.0038%
Change 5-day change 1-year change 3-year change Capi.($)
-3.67%-8.05%+329.83%+451.10% 1.32B
+5.04%+3.27%+50.62%+105.43% 66.93B
+1.64%-0.18%+36.02%+76.81% 61.97B
-3.19%+0.36%-12.44%+369.97% 28.26B
+4.55%-0.08%+34.70%+17.28% 24.59B
+2.22%+0.69%+1.49%-12.71% 24.3B
+1.15%-1.17%+18.94%-21.92% 19.41B
-7.03%-9.16%+161.91%+303.00% 16.77B
+3.44%-1.68%-5.00%+541.17% 14.18B
+4.81%+6.19%-3.12%+860.73% 14B
Average +0.90%-3.90%+61.30%+269.09% 27.17B
Weighted average by Cap. +1.95%-2.84%+35.20%+174.31%

Financials

2026 *2027 *
Net sales 126M 109M 103M 93.18M 175M 12.04B 176M 1.23B 473M 6.11B 472M 461M 19.42B 198M 171M 162M 147M 275M 18.96B 277M 1.93B 744M 9.62B 743M 727M 30.58B
Net income 63.3M 54.85M 51.76M 46.96M 88.09M 6.07B 88.73M 618M 238M 3.08B 238M 233M 9.78B 79.47M 68.86M 64.98M 58.95M 111M 7.62B 111M 776M 299M 3.86B 298M 292M 12.28B
Net Debt - -
Logo Omeros Corporation
Omeros Corporation is a clinical-stage biopharmaceutical company. The Company focuses on discovering, developing, and commercializing first-in-class small-molecule and protein therapeutics for both large-market and orphan indications, with a particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. Its clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program. Its commercial product, YARTEMLEA, is the approved inhibitor of the lectin pathway of complement. YARTEMLEA is used for the treatment of TA-TMA in adults and in children ages two years and older. YARTEMLEA selectively inhibits MASP-2, blocking pathway activation while preserving classical and alternative complement pathway functions.
Employees
175
Date Price Change Volume
14/09/26 $17.57 -3.88% 1,101,862
11/09/26 $18.28 -1.67% 1,014,308
10/09/26 $18.59 -4.13% 1,231,840
09/09/26 $19.39 +1.41% 1,531,324
08/09/26 $19.12 +0.90% 1,015,537
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
18.28USD
Average target price
33.00USD
Spread / Average Target
+80.53%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. OMER Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!